CA
NZ
UK
AU
IND
US
The weak spot was joint replacement. Hip sales fell 1 percent while knee sales rose 1.1 percent, whereas Johnson & Johnson (NYSE:JNJ) reported knee growth of 2.5 percent and hip growth of 3.2 percent in the same period, according to published coverage. Lobo said …
The medical benefits ratio compares medical costs with premiums, so a 240 basis point rise means a larger share of each premium dollar went to care. The company cited Part D seasonality, the timing of clinical investments, elevated appeals and disputes, and higher costs …
Key HighlightsAstraZeneca (NYSE:AZN) reported third quarterRevenueof USD 16.209 billion, up 7 percent, with core EPS of USD 2.79, up 17 percent, and reconfirmed full-year guidance of mid-to-high single digit revenue growth.Sanofi (NASDAQ:SNY) reported third quarter sales of 14.444 billion euro, up 14.3 percent at …
● No company-specific news was found.
● Pacira is best known for Exparel, a long-acting non-opioid pain medication.
● The company raised its 2026 outlook.
Key Highlights● Enovis slid on Friday, October 30, 2026, in closing data.● No company-specific news was found.● No catalyst was cited.● Enovis is an orthopedics-focused medical technology company.Enovis (NYSE:ENOV) slid on Friday, October 30, 2026, according to closing data compiled by market data. No …
● Regeneron was the S&P 500's top gainer.
● No company-specific catalyst could be confirmed.
● The application covers sickle cell disease.
Please wait processing your request...